
	Where results make sense

Topic: AstraZeneca plc

Related Topics

AstraZeneca

List of European companies

British companies

Imperial Chemical Industries PLC

Lists of companies

Swedish Match

Astra

Anglo American plc

GlaxoSmithKline

Pharmaceutical company

Wolseley plc

List of Swedish companies

Autoliv

Bure Equity

Biovail

In the News (Wed 25 Nov 09)

Northern Trust

Marvin Harrison

Peter Chernin

Gary Locke

Match Play

Penelope Cruz

Mickey Rourke

AR Rahman

Danny Boyle

Hugh Jackman

	AstraZeneca - Wikipedia, the free encyclopedia
		AstraZeneca develops, manufactures, and sells pharmaceuticals to treat disorders in the gastrointestinal, cardiac and vascular, neurological and psychiatric, infection, respiratory, pathological inflammation and oncology areas.
		AstraZeneca is the major sponsor for Breast Cancer Awareness Month which focuses on early detection and treatment[4].
		The Board of AstraZeneca PLC announces the appointment of David R Brennan as Chief Executive with effect from 1 January 2006 upon the retirement at that time of Sir Tom McKillop.
	en.wikipedia.org /wiki/AstraZeneca (608 words)

	ASTRAZENECA PLC - Full Company Description \| Reuters.com
		AstraZeneca PLC (AstraZeneca), incorporated on June 17, 1992, discovers, develops, manufactures and markets prescription pharmaceuticals for various areas of healthcare, including cardiovascular, gastrointestinal, neuroscience, oncology, respiratory and inflammation, and infection.
		AstraZeneca has a range of compounds in early development, and a total of 17 projects in Phase I, 15 projects in Phase II and 29 projects in Phase III development.
		AstraZeneca is focusing on developing approaches to treating GERD, IBD and functional gastrointestinal disorders (FGD), such as irritable bowel syndrome (IBS) and functional dyspepsia.
	reuters.investor.reuters.com /FullDesc.aspx?ticker=AZN&target=companyprofile/fulldescription (1946 words)

	AstraZeneca Q1 tops forecast, ups 2006 outlook - Boston.com
		AstraZeneca Plc posted record quarterly profits on Thursday and raised its earnings forecast for 2006, boosted by strong demand for established medicines such as Seroquel for schizophrenia.
		AstraZeneca also raised its 2006 EPS forecast to $3.60-3.90 from $3.40-3.60 previously, assuming no generic versions of heart drug Toprol XL are launched in the United States in 2006.
		AstraZeneca shares trade at around 16 times forecast 2006 earnings, according to Reuters Estimates, which is a modest discount to the European sector <.SXDP> average of 17 times.
	www.boston.com /news/world/europe/articles/2006/04/27/astrazeneca_q1_tops_forecast_ups_2006_outlook (506 words)

	AZN Key Developments: Investing - MSN Money
		AstraZeneca also announced the commencement of the Subsequent Offer Period, which is expected to remain open for acceptance until such time as the compulsory acquisition procedures are completed or until 3.00pm (London time) on September 22, 2006, whichever occurs earlier.
		AstraZeneca PLC announced that it plans to further expand its Patient Assistance Program (PAP) to include seniors with limited incomes who are enrolled in a Medicare Part D drug coverage plan.
		AstraZeneca PLC announced that the U.S. Food and Drug Administration (FDA) has approved the use of NEXIUM (esomeprazole magnesium) delayed release capsules, in children ages 12 to 17 for the short-term treatment of gastroesophageal reflux disease (GERD).
	news.moneycentral.msn.com /ticker/sigdev.asp?Symbol=AZN (1142 words)

	AstraZeneca strikes drug deals with Abraxis - Boston.com
		AstraZeneca Plc said on April 27 it had agreed to sell its U.S. anesthetics and analgesic product portfolio to Abraxis BioScience for $350 million.
		AstraZeneca said it had also agreed to buy the rights to co-promote breast cancer drug Abraxane in the United States from Abraxis BioScience for $200 million.
		AstraZeneca said the products it was selling to Abraxis BioScience had U.S. sales of approximately $217 million in 2005.
	www.boston.com /news/world/europe/articles/2006/04/27/astrazeneca_to_sell_us_anesthetics_for_350_mln (334 words)

	Leerink Swann & Company Initiates Coverage of AstraZeneca PLC (NYSE: AZN)
		His investment rating is based on his belief that AstraZeneca's current valuation offers an attractive entry point for a company with top-tier EPS growth prospects and limited risk from generic drugs.
		AstraZeneca PLC (NYSE:AZN) is one of the world's leading pharmaceutical companies.
		AstraZeneca's broad portfolio of medicines includes many world leaders such as Nexium for gastrointestinal disease and Crestor for high cholesterol.
	www.leerink.com /news/20050713.htm (238 words)

	MicroStrategy - AstraZeneca: MicroStrategy Customer Success Story (Site not responding. Last check: 2007-10-23)
		London-based AstraZeneca is using MicroStrategy to report on and analyze data in its sales prescriber data warehouse (SPW).
		AstraZeneca employees can pull up reports through its salesforce portal or run queries, with 20-second average response times, against a one-terabyte Oracle® data warehouse.
		AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services.
	www.microstrategy.com /Customers/Successes/astrazeneca.asp (327 words)

	RedOrbit - Health - AstraZeneca: NCI May Halt Iressa Trial (Site not responding. Last check: 2007-10-23)
		NEW YORK - AstraZeneca PLC said the National Cancer Institute may halt a trial of its cancer drug Iressa because the drug failed to prolong patients' lives in a previous study.
		AstraZeneca said the NCI had been funding a separate trial of lung cancer patients who were stable after receiving chemotherapy to see if Iressa could help prolong their lives.
		AstraZeneca spokeswoman Mary Lynn Carver said that NCI was considering halting the trial because the results the company released in December called into question whether patients in the study would live longer.
	www.redorbit.com /news/display/?id=144701&source=r_health (260 words)

	Pomerantz - Current Cases
		AstraZeneca is a pharmaceutical company which researches, develops, manufactures, and markets prescription pharmaceuticals and healthcare services.
		The complaint alleges that throughout the Class Period defendants issued numerous materially false and misleading statements concerning the results of the clinical trials of the investigational oral anticoagulant Exanta, and the status and likelihood of the approval of the New Drug application for Exanta.
		If you puchased the securities of AstraZeneca PLC during the Class Period, you have until March 28, 2005 to ask the Court to appoint you as lead plaintiff for the Class.
	www.pomerantzlaw.com /publications/caseUser2.cfm?pubid=411 (322 words)

	Stockholders v AstraZeneca PLC Lawsuit \| Kahn Gauthier Swick, LLC (Site not responding. Last check: 2007-10-23)
		A class action has been filed against AstraZeneca PLC (NYSE:AZN), a pharmaceutical company and certain of its officers and directors by stockholders who purchased the company's common stock between April 2nd, 2003 and October 11th, 2004.
		AstraZeneca is a pharmaceutical research company specializing in research and development of drugs to treat cardiovascular, gastrointestinal, neuroscience, oncology, respiratory and inflammation and infection disorders.
		If you bought AstraZeneca PLC securities between April 2nd, 2003 and October 11th, 2004, inclusive, and would like to obtain information about the lawsuit, then you are invited to call (866) 467-1400 to speak with an attorney.
	www.kglg.com /case/case.asp?lngCaseId=4221 (478 words)

	delawareonline ¦ The News Journal ¦ AstraZeneca to pull Exanta (Site not responding. Last check: 2007-10-23)
		AstraZeneca PLC said Tuesday it will withdraw its Exanta blood-thinner and cease clinical trials amid concerns it could cause serious liver damage.
		AstraZeneca's inability to get FDA approval for Exanta won't help that effort, said one analyst who follows the company.
		AstraZeneca's hopes for Exanta were dashed when the FDA rejected the company's new drug application.
	www.delawareonline.com /apps/pbcs.dll/article?AID=/20060215/BUSINESS/602150358/1003 (526 words)

	Parker & Waichman LLP and Aylstock, Witkens & Sasser PLC File Class Action against AstraZeneca PLC on Behalf of ...
		The lawsuit alleges that AstraZeneca was aware that Seroquel caused a high occurrence of diabetes, but failed to adequately warn doctors or patients in the United States.
		AstraZeneca has not adopted this safer, more accurate and comprehensive label for the U.S. distribution of Seroquel.
		AstraZeneca offered incentives to doctors and other medical professionals to increase the number of Seroquel prescriptions that were written.
	www.ereleases.com /pr/2003-08-28c.html (738 words)

	AstraZeneca Group plc stock - The gift of a single share.
		AstraZeneca Group plc stock - The gift of a single share.
		AstraZeneca PLC is an international research-based pharmaceutical company engaged in the development, manufacture and marketing of ethical (prescription) pharmaceutical products.
		In addition to its products and research and development efforts, AstraZeneca provides health education information, support services and health guidance to millions of Americans through public awareness campaigns.
	www.singleshare.com /stocks/azn.shtml (130 words)

	AstraZeneca PLC First Quarter Results 2003
		Disclosure Notice: The preceding forward-looking statements relating to expectations for earnings and business prospects for AstraZeneca PLC are subject to risks and uncertainties, which may cause results to differ materially from those set forth.
		The accounting policies applied are those set out in AstraZeneca PLC's 2002 Annual Report and Form 20-F. These interim financial statements do not constitute statutory accounts within the meaning of Section 240 of the Companies Act 1985.
		As part of AstraZeneca's objective to align with best accounting practice, cash discounts arising from prompt payments of invoices were reclassified from cost of sales to sales for the year ended 31 December 2002.
	www.prnewswire.com /cgi-bin/stories.pl?ACCT=104&STORY=/www/story/04-30-2003/0001937094&EDATE= (2823 words)

	Biospace.com (Site not responding. Last check: 2007-10-23)
		Novartis AG Gets OK To Sell Version Of AstraZeneca PLC (AZN)'s Toprol-XL Novartis AG, the world’s second-largest generic drug maker, won U.S. approval of a version of AstraZeneca Plc’s Toprol-XL hypertension medicine.
		AstraZeneca PLC (AZN) Release: Aromatase Inhibitors Declared Superior To Tamoxifen In The Adjuvant Treatment Of Early Breast Cancer
		LONDON -(Dow Jones)- AstraZeneca Monday announced the U.S. Food and Drug Administration (FDA) has approved SYMBICORT(R) (budesonide/formoterol) for the maintenance treatment of asthma in patients age 12 and older.
	www.biospace.com /news_company.aspx?CompanyID=48304 (676 words)

	AZN - AstraZeneca PLC - Google Finance
		AstraZeneca PLC (AstraZeneca) discovers, develops, manufactures and markets prescription pharmaceuticals for various areas of healthcare, including cardiovascular, gastrointestinal, neuroscience, oncology, respiratory and inflammation, and infection.
		AstraZeneca Plc (AZN) shares gained as much as 2 percent on Monday after it wonUS approval for two-in-one asthma drug Symbicort a year earlier...
		AstraZeneca plc (AZN): Edward Owens Reduces His Holdings in AZN
	google.com /finance?cid=1966410 (358 words)

	The Pomerantz Firm Charges AstraZeneca PLC with Securities Fraud -- AZN
		AstraZeneca is a pharmaceutical company which researches, develops, manufactures and markets prescription pharmaceuticals and the supply of healthcare services.
		During the Class Period, AstraZeneca touted the purportedly positive results from the clinical trials of Exanta, claiming that they were indicative of a safe and effective new direct oral anticoagulant.
		If you purchased the securities of AstraZeneca PLC during the Class Period, you have until March 28, 2005 to ask the Court to appoint you as lead plaintiff for the Class.
	www.primezone.com /newsroom?d=74644 (855 words)

	BioPharmaLink profile of AstraZeneca PLC, United Kingdom,
		AstraZeneca is one of the world's top five ethical pharmaceutical companies, active in more than 100 countries.
		We have over 47,000 employees worldwide, who are engaged in the research, development, manufacture and marketing of pharmaceuticals and the supply of healthcare services.
		The corporate headquarters of AstraZeneca are located in the UK, The research and development headquarters of AstraZeneca are located in Sweden.
	www.biopharmalink.com /companies/1437.htm (89 words)

	ASTRAZENECA PLC
		David Brennan is an Executive Director of AstraZeneca PLC and Executive Vice President, North America, responsible for the company’s business in the US and Canada.
		Louis Schweitzer, Chairman of AstraZeneca PLC, said: “The Board’s appointment of David Brennan is the outcome of a rigorous selection process from a very strong list of candidates.
		Executive Vice-President, North America, AstraZeneca PLC since 2001.
	www.astrazeneca.com /pressrelease/4992.aspx (251 words)

	RedOrbit - Health - AstraZeneca: Stroke Drug Shows Promise
		AstraZeneca, Europe's third-largest drugmaker, said tests of the drug Cerovive showed that an improvement in post-stroke disabilities was significant compared to a placebo when measured using the so-called modified Rankin test, which examines mental function.
		AstraZeneca said that, depending on the final data results, it intends to go ahead with current plans to file regulatory submissions for Cerovive in the second half of 2006.
		Shares in AstraZeneca were up 0.2 percent at $44.63 in morning trading on the London Stock Exchange.
	www.redorbit.com /news/display/?id=148035&source=r_health (457 words)

	Astrazeneca Plc Nexium
		RNS Number:7666F AstraZeneca PLC 29 November 2004 NEXIUM RECEIVES FDA APPROVAL FOR RISK REDUCTION OF NSAID-ASSOCIATED STOMACH ULCERS AstraZeneca today announced that a new indication for its prescription proton pump inhibitor Nexium(R) (esomeprazole magnesium) has been approved by the US Food and Drug Administration (FDA).
		AstraZeneca announced that the European Union (Mutual Recognition Procedure (MRP) for new indications for Nexium had been successfully finalized in September this year.
		The new indications in the EU are for the healing of gastric ulcers and, for patients at risk, the prevention of gastric and duodenal ulcers, associated with NSAID therapy.
	www.advfn.com /news_nexium_9538440.html (601 words)

	Novartis AG and Astrazeneca PLC (Site not responding. Last check: 2007-10-23)
		AstraZeneca is a corporation incorporated under the laws of the United Kingdom, is not a reporting issuer under the Legislation of any of the Jurisdictions and has no present intention of becoming a reporting issuer in any of the Jurisdictions.
		Residents in the Jurisdictions holding AstraZeneca Shares received, in connection with the Transactions, the same disclosure documentation as that received by holders of AstraZeneca Shares with addresses in the United Kingdom.
		Residents in the Jurisdictions holding Novartis ADSs and AstraZeneca ADSs received, in connection with the Transactions, the same disclosure documentation as that received by holders of Novartis ADSs and AstraZeneca ADSs, respectively, with addresses in the United States.
	www.msc.gov.mb.ca /orders/novartis.html (1473 words)

	StockHouse USA
		U.S. shares of AstraZeneca PLC set a new 52-week high Wednesday after marketing research firms said the British drug maker's heartburn medication Nexium saw a significant rise in sales.
		AstraZeneca said Monday it has agreed to buy Cambridge Antibody Technologies at a company value of 702 million pounds, or about $1.3 billion, in a move expected to boost the Anglo-Swedish pharmaceutical giant's product pipeline.
		AstraZeneca said Thursday it has dropped an experimental treatment for the glucose and lipid abnormalities associated with type 2 diabetes because data suggested it affected kidney function during late-stage clinical trials.
	www.stockhouse.com /comp_info.asp?symbol=AZN (502 words)

	Targacept and AstraZeneca Announce Global License and Research Collaboration Agreement
		While the parties will collaborate to identify novel candidate drugs, AstraZeneca will be primarily responsible for and will fund the development and commercialization of TC-1734 and any compounds that arise out of the four- year research collaboration.
		About AstraZeneca AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services.
		The AstraZeneca neuroscience pipeline includes leading approaches for the treatment of depression and anxiety, overactive bladder, dementia, stroke, pain control and anaesthesia.
	www.prnewswire.com /cgi-bin/stories.pl?ACCT=104&STORY=/www/story/12-28-2005/0004239937&EDATE= (746 words)

	Bloomberg.com: U.K. (Site not responding. Last check: 2007-10-23)
		June 2 (Bloomberg) -- AstraZeneca Plc, Europe's second- largest drugmaker, said early tests of its new Iressa lung cancer treatment showed promise against other types of the illness, including breast, brain and advanced colorectal tumors.
		In breast cancer, AstraZeneca presented data from two phase II studies of patients who had not responded to previous treatments.
		AstraZeneca is also looking at the drug in brain cancer.
	quote.bloomberg.com /apps/news?pid=10000102&sid=a..etInMfVRU&refer=uk (275 words)

	Complaint : U.S. v. Syngenta AG, Astrazeneca PLC, Koninklijke Cooperatie Cosun U.A., and Advanta B.V.
		Syngenta AG, Astrazeneca PLC, Koninklijke Cooperatie Cosun U.A., and Advanta B.V. This document is available in three formats: this web page (for browsing content),
		AstraZeneca PLC is a private limited company with its headquarters in London, England.
		AstraZeneca PLC is the ultimate parent entity of AstraZeneca Holdings B.V., which holds 50% of the shares of Advanta.
	www.usdoj.gov /atr/cases/f205100/205199.htm (1552 words)

	The Hindu Business Line : AstraZeneca Plc to sue Ranbaxy on ulcer drug
		ASTRAZENECA Plc has decided to file a lawsuit in a New Jersey District Court against Ranbaxy Laboratories Ltd for `wilful infringement' of its patents protecting Nexium (esomeprazole magnesium) used in the treatment of heartburn and ulcers.
		The drug, which is protected by six patents that expire between 2014 and 2019, generated revenue of $3.8 billion in 2004.
		Besides this, AstraZeneca is already fighting a challenge to Nexium from Hyderabad-based Dr Reddy's Laboratories Ltd.
	www.thehindubusinessline.com /2005/11/23/stories/2005112302020200.htm (620 words)

	AstraZeneca PLC (Site not responding. Last check: 2007-10-23)
		AstraZeneca Canada Inc. ("AstraZeneca Canada") is a wholly owned indirect subsidiary of the Filer and is incorporated under the laws of Ontario.
		Any person who is an employee or director of the Filer or any of its designated subsidiaries (including AstraZeneca Canada) may be invited by the remuneration committee of the Filer to participate in the Plan ("Eligible Employee").
		The Filer and AstraZeneca Canada are not reporting issuers under the Legislation of any Jurisdiction and have no present intention of becoming reporting issuers under the Legislation of any Jurisdiction.
	www.msc.gov.mb.ca /orders/astrazeneca.html (567 words)

Try your search on: Qwika (all wikis)